Overall, data emerging from pre-clinical work indicates that IBD is marked by a high expression of Smad7 in the inflamed gut, which results in defective anti-inflammatory activity of TGF-β1 and amplification of the ongoing mucosal inflammation. This evidence concerns the gene TGFB1 and inflammatory bowel disease.